IRON — Disc Medicine, Inc. Stock Price, Chart & AI Report

Negative May 26, 2026 • 01:41 UTC GlobeNewswire Inc. • Rosen Law Firm

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, rejecting the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused Disc Medicine's stock to fall 22%. The firm is preparing a class action lawsuit to recover investor losses.

IRON securities class action FDA rejection Complete Response Letter bitopertin stock decline investor losses drug approval

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, citing uncertainties requiring additional evidence. This regulatory setback resulted in a 22% stock price decline and triggered a securities class action investigation for allegedly issuing materially misleading business information.

Negative May 20, 2026 • 02:31 UTC GlobeNewswire Inc. • Globe Newswire

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter rejecting the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused Disc Medicine's stock to plummet 22%. The firm is preparing a class action lawsuit to recover investor losses.

IRON securities fraud class action lawsuit FDA rejection Complete Response Letter bitopertin stock price decline investor losses

Sentiment note

The company received an FDA Complete Response Letter rejecting its drug application, indicating the bitopertin program cannot be approved without additional evidence. This regulatory setback resulted in a 22% stock price decline and triggered securities litigation investigation for allegedly issuing materially misleading business information.

Negative May 13, 2026 • 23:32 UTC GlobeNewswire Inc. • The Rosen Law Firm

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, stating it could not approve the company's bitopertin drug application due to uncertainties requiring additional evidence. The stock fell 22% following the announcement. The firm is preparing a class action lawsuit to recover investor losses.

IRON securities class action FDA Complete Response Letter bitopertin stock decline investor losses drug approval shareholder litigation

Sentiment note

FDA rejected the new drug application for bitopertin program, citing uncertainties requiring additional evidence. Stock price fell 22% on the announcement, and the company is now subject to a securities class action investigation for allegedly issuing materially misleading business information.

Negative May 11, 2026 • 00:33 UTC GlobeNewswire Inc. • Rosen Law Firm

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, stating it could not approve the company's bitopertin drug application due to uncertainties requiring additional evidence. The news triggered a 22% stock price decline. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

IRON securities class action FDA Complete Response Letter bitopertin drug approval investor losses stock decline

Sentiment note

The company received an FDA Complete Response Letter rejecting its new drug application for bitopertin, indicating regulatory setback and uncertainty. The stock fell 22% on the announcement, and securities litigation is being pursued on behalf of shareholders alleging materially misleading business information.

Negative May 5, 2026 • 00:15 UTC GlobeNewswire Inc. • Rosen Law Firm

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine (IRON), Immutep Ltd. (IMMP), and New Era Energy & Digital, Inc. (NUAI) for allegedly issuing materially misleading business information. Disc Medicine's stock fell 22% following an FDA Complete Response Letter on its bitopertin program on February 13, 2026. The firm is preparing class action lawsuits seeking recovery of investor losses.

IRON IMMP NUAI NUAIW securities class action FDA Complete Response Letter investor losses materially misleading information

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, citing uncertainties requiring additional evidence. Stock price fell 22% on the announcement, indicating significant investor losses and regulatory setback.

Negative Apr 25, 2026 • 19:10 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages ODDITY Tech Ltd. Investors With Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action– ODD

Rosen Law Firm is soliciting investors who suffered losses in ODDITY Tech Ltd., Pinterest, Inc., and Disc Medicine, Inc. to join securities class action lawsuits. The firm alleges that ODDITY Tech made false statements about its business performance due to an algorithm change by its largest advertising partner that increased customer acquisition costs. Lead plaintiff deadlines and contingency fee arrangements are available for eligible investors.

ODD PINS IRON securities class action investor losses false statements customer acquisition costs algorithm change

Sentiment note

Company is mentioned as subject to ongoing securities claims investigation by Rosen Law Firm on behalf of shareholders, indicating potential legal and financial issues.

Negative Apr 25, 2026 • 16:25 UTC GlobeNewswire Inc. • Rosen Law Firm

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, rejecting the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused Disc Medicine's stock to fall 22%. The firm is preparing a class action lawsuit to recover investor losses.

IRON securities class action FDA rejection Complete Response Letter bitopertin stock decline investor losses drug approval

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, indicating the drug cannot be approved without additional evidence. This regulatory setback caused a 22% stock price decline and triggered securities litigation, representing a significant business and financial setback.

Neutral Apr 22, 2026 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight

The polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.

PTGX TAK MRK IONS polycythemia vera market expansion clinical trials hepcidin modulators

Sentiment note

Developing DISC-3405 in Phase II trials for polycythemia vera; early-stage monoclonal antibody approach with potential for patients inadequately managed with phlebotomy, but timeline uncertain.

Positive Apr 21, 2026 • 14:00 UTC GlobeNewswire Inc. • Na

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine will present Phase 2 RALLY-MF trial data for DISC-0974, an anti-hemojuvelin antibody for treating anemia in myelofibrosis, at the ASCO Annual Meeting on June 2, 2026. The company reported that initial data showed unprecedented anemia response rates in this hard-to-treat patient population, with additional patient data to be presented at the conference.

IRON DISC-0974 RALLY-MF myelofibrosis anemia Phase 2 trial ASCO Annual Meeting anti-hemojuvelin antibody

Sentiment note

The company announced presentation of Phase 2 trial data showing 'unprecedented' anemia response rates in a difficult-to-treat patient population. This represents meaningful clinical progress for their lead candidate DISC-0974, indicating potential therapeutic efficacy and supporting continued development momentum.

Negative Apr 19, 2026 • 01:59 UTC GlobeNewswire Inc. • Rosen Law Firm

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, that rejected the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused Disc Medicine's stock to plummet 22%. The firm is preparing a class action lawsuit to recover investor losses.

IRON securities fraud FDA rejection class action lawsuit bitopertin Complete Response Letter stock decline investor losses

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, citing uncertainties requiring additional evidence. This regulatory setback resulted in a 22% stock price decline and triggered a securities class action investigation for allegedly issuing materially misleading business information to investors.

Negative Apr 7, 2026 • 20:59 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON

Pomerantz LLP is investigating potential securities fraud claims against Disc Medicine, Inc. (IRON) following significant stock price declines. The company's stock fell 7.84% on January 15, 2026 after Reuters reported FDA safety and efficacy concerns about a drug under development. Stock fell further 21.91% on February 13, 2026 when the FDA issued a Complete Response Letter rejecting the New Drug Application for bitopertin, citing insufficient evidence of efficacy.

IRON securities fraud class action lawsuit FDA rejection drug development stock price decline Complete Response Letter bitopertin

Sentiment note

Company faced significant stock price declines (7.84% and 21.91%) following FDA safety concerns and rejection of drug application. Securities fraud investigation initiated by major law firm indicates serious regulatory and legal challenges.

Negative Mar 27, 2026 • 22:35 UTC GlobeNewswire Inc. • Rosen Law Firm

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm announced an investigation into potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following the FDA's issuance of a Complete Response Letter on February 13, 2026, regarding its bitopertin program. The rejection led to a 22% stock price decline. The firm is preparing a class action lawsuit to recover investor losses.

IRON securities fraud FDA rejection class action lawsuit Complete Response Letter bitopertin program stock price decline investor losses

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, indicating uncertainties requiring additional evidence. The stock fell 22% on the news, and the company is now subject to a securities class action investigation for allegedly issuing materially misleading business information.